BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis

NEXT STORY
Burning Rock to be Added to MSCI China Index
PREV STORY
Strong Success of the Tender Offer Initiated by Alphatec Holdings for Common Shares and OCEANEs of EOS IMAGING
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TCR2 Therapeutics Announces Partnership with the National Cancer Institute for Phase 1/2 Trial of TC-210

author_avatar
NASDAQ Market News

Branded Generics Market is expected to witness a 7.3% CAGR and US$ 410 Bn by 2026

Global Sales of Branded Generics Will Amass More Than US$ 400 Billion in Revenues ...

author_avatar
NASDAQ Market News

Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

author_avatar
NASDAQ Market News